Consort Medical Signs Supply Agreement for Integrated Dose Counter
Consort Medical plc recently announced the conclusion of a significant new commercial supply agreement for its proprietary integrated dose counter (IDC) system. The multi-year supply agreement covers supply of both the IDC actuator and the pressurized metered dose inhaler (pMDI) valve. This IDC program represents the first commercial oral variant of the device, which is already approved and marketed for a nasally delivered product.
Dose-counting devices fulfil an important patient and compliance need to let patients know if their device contains sufficient drug and to indicate when they need to seek a further prescription. It provides patients with a reliable, easy-to-read indication of how many doses are left inside the canister in line with FDA guidance.
“Consort Medical has a long heritage of excellence, reliability, and innovation, and we strive to be the partner of choice for pharmaceutical companies, enabling them to implement drug delivery technologies that can streamline and accelerate the route to market for their drugs. With the conclusion of this agreement for our IDC device, we have reinforced the ongoing strength of our respiratory device franchise, in particular, in the pMDI segment, and created a significant business opportunity.”
The device will be manufactured in the Consort Medical company Bespak’s existing IDC facility at King’s Lynn. The project will be referred to as (IDC300).
Bringing Aesica together with Bespak within the Consort Medical group builds on Bespak’s rich drug delivery device heritage over the last 50 years and Aesica’s decade-long expansion into a leading European pharmaceutical CDMO. Today, Consort Medical is a leading, global, single-source drug and delivery device CDMO. Optimizing world-class drug delivery device development and manufacture, together with API and finished dose drug formulation and manufacture, within the same group streamlines and accelerates pharmaceutical customers’ drug route to market. Consort Medical remains at the leading edge of innovation and is committed to investing in patient- and customer-driven innovation with the potential to create new treatments, new markets, and new opportunities. For more information, visit www.consortmedical.com.
Total Page Views: 1004
